GLP-1 Receptor Agonists and Muscle Mass: A Narrative Review of What Body Composition Data Do and Do Not Show
DOI:
https://doi.org/10.5281/zenodo.22261252Keywords:
GLP-1 receptor agonists, Lean mass, Body composition, Muscle function, Sarcopenic obesityAbstract
Body composition analyses of incretin-based weight treatments have produced an alarming headline: 39 to 40 per cent of the
weight lost in two semaglutide programmes was lean mass. Three findings complicate it. First, the proportion of lean mass
relative to total body mass increased despite the absolute loss, so composition improved rather than deteriorated. Second, the
estimate is unstable: across six studies of 1,541 adults, lean mass accounted for anywhere between almost none and 40 per cent of
weight lost, with the same drug class and the same measurement method. Third, lean mass on a scan is not muscle, since the
compartment includes body water and non-muscle organs, so a fall in it does not by itself establish loss of muscle or sarcopenia.
Where function was measured rather than inferred, a prospective cohort of 106 patients found handgrip strength rose by 4.5 kg
over 12 months and sarcopenic obesity fell from 49 to 33 per cent. This review sets out what these data support and what they do
not.
References
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. "Once-weekly semaglutide in adults with overweight or obesity". N Engl J Med 384(2021):989-1002.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. "Tirzepatide once weekly for the treatment of obesity". N Engl J Med 387(2022):205-216.
Gudzune KA, Kushner RF. "Medications for obesity: a review". JAMA 332(2024):571-584.
Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. "Muscle matters: the effects of medically induced weight loss on skeletal muscle". Lancet Diabetes Endocrinol 12(2024):785-787.
Neeland IJ, Linge J, Birkenfeld AL. "Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies". Diabetes Obes Metab 26(2024):16-27.
DeFronzo RA, Tripathy D. "Skeletal muscle insulin resistance is the primary defect in type 2 diabetes". Diabetes Care 32(2009):S157-S163.
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. "Sarcopenia: revised European consensus on definition and diagnosis". Age Ageing 48(2019):16-31.
Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, et al. "Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement". Clin Nutr 41(2022):990-1000.
Systematic review authors. "A systematic review of the effect of semaglutide on lean mass: insights from clinical trials". Expert Opin Pharmacother 25(2024):611-619.
Wilding JPH, Batterham RL, Calanna S, Van Gaal LF, McGowan BM, Rosenstock J, et al. "Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study". J Endocr Soc 5(2021):A16-A17.
Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, et al. "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight". Diabetes Obes Metab 27(2025):2720-2729.
Lean mass commentary authors. "Semaglutide and GLP-1: effects on lean body mass still unclear". Drug Discovery Trends (2024).
Case series authors. "Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: a case series". Obes Sci Pract (2025).
Digital phenotyping investigators. "Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping". medRxiv (2026).
Comparative meta-analysis authors. "Tirzepatide versus semaglutide for weight loss in overweight and obese adults: a systematic review and meta-analysis of direct comparative studies". Cureus 17(2025):e85147.
Pandey A, Patel KV, Vaduganathan M, Sarma S, Haykowsky MJ, Berry JD, et al. "Physical activity, fitness, and obesity in heart failure with preserved ejection fraction: effects of pharmacotherapy on body composition". JACC Heart Fail 6(2018):975-982.
Heymsfield SB, Gonzalez MC, Lu J, Jia G, Zheng J. "Skeletal muscle mass and quality: evolution of modern measurement concepts in the context of sarcopenia". Proc Nutr Soc 74(2015):355-366.
Bosy-Westphal A, Muller MJ. "Assessment of fat and lean mass by quantitative magnetic resonance: a future technology of body composition research?". Curr Opin Clin Nutr Metab Care 18(2015):446-451.
SEMALEAN investigators. "Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study". Diabetes Obes Metab (2025).
Novartis Pharmaceuticals. "Safety and efficacy of bimagrumab and semaglutide in adults who are overweight or obese". ClinicalTrials.gov NCT05616013 (2024).
Chaston TB, Dixon JB, O Brien PE. "Changes in fat-free mass during significant weight loss: a systematic review". Int J Obes 31(2007):743-750.
Weiss EP, Jordan RC, Frese EM, Albert SG, Villareal DT. "Effects of weight loss on lean mass, strength, bone, and aerobic capacity". Med Sci Sports Exerc 49(2017):206-217.
Cava E, Yeat NC, Mittendorfer B. "Preserving healthy muscle during weight loss". Adv Nutr 8(2017):511-519.
Villareal DT, Aguirre L, Gurney AB, Waters DL, Sinacore DR, Colombo E, et al. "Aerobic or resistance exercise, or both, in dieting obese older adults". N Engl J Med 376(2017):1943-1955.
Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. "A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans". Endocrinol Metab 34(2019):247-262.
Ida S, Kaneko R, Imataka K, Murata K. "Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus". Curr Diabetes Rev 17(2021):293-303.
Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity". Diabetes Obes Metab 19(2017):1242-1251.
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)". Lancet 402(2023):613-626.
Linge J, Birkenfeld AL, Neeland IJ. "Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or detrimental change?". Diabetes Obes Metab 26(2024):4023-4025.
Conte C, Hall KD, Klein S. "Is weight loss-induced muscle mass loss clinically relevant?". JAMA 332(2024):9-10.
Batsis JA, Villareal DT. "Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies". Nat Rev Endocrinol 14(2018):513-537.
McCarthy D, Berg A. "Weight loss strategies and the risk of skeletal muscle mass loss". Nutrients 13(2021):2473.
Nunes EA, Colenso-Semple L, McKellar SR, Yau T, Ali MU, Fitzpatrick-Lewis D, et al. "Systematic review and meta-analysis of protein intake to support muscle mass and function in healthy adults". J Cachexia Sarcopenia Muscle 13(2022):795-810.
Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. "Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial". Nat Med 29(2023):2909-2918.
